bioRxivMicrobiologyPreprint
Protective efficacy of calcium phosphate nanoparticle adsorbed bivalent subunit vaccine of Pasteurella multocida against homologous challenge in mice
Abstract
Swine pasteurellosis, caused by Pasteurella multocida capsular types A and D, causes heavy economic loss to the pig farmers. The vaccine presently used is abacterin of Pasteurella multocida capsular type B that is proven to be effective against bovine pasteurellosis. However, its efficacy against swine pasteurellosis is questionable. The present study was carried out to evaluate the efficacy of calcium phosphate nanoparticle adjuvanted bivalent subunit vaccine prepared from Pasteurella multocida capsular types A and D along with a monovalent subunit vaccine prepared from Pasteurella multocida capsular type B in mice. The Alum precipitated bacterin vaccine was used as the control. The bivalent subunit vaccine comprising the immune components of both the capsular types showed significantly higher IgG response than either of the other two vaccines. Both the calcium phosphate nanoparticle adjuvanted vaccines could elicit 100% protection in mice against homologous challenges but the aluminum hydroxide adjuvanted bacterin vaccine could not elicit significant protection. Based on this preliminary work, it was concluded that the bivalent subunit vaccine would be a better option for immunization of swine against swine pasteurellosis. IMPORTANCE OF THE WORKThe swine pasteurellosis is an important economic disease affecting the pig population in the North-eastern part of India that contributes the major pig population. The disease is caused by Serotype A and D of Pasteurella multocida. At present the inactivated vaccine is used that is actually developed against P52 strain of serotype B:2 of Pasteurella multocida, which is mainly involved in haemorrhagic septicaemia (or bovine pasteurellosis) that affects the cattle, buffaloe, sheep and goat. As a result, the present vaccine does not give sufficient protection in pigs but gives significant protection in cattle, buffaloe, sheep and goat. Hence, there is a need of development of vaccine that can address specifically swine pasteurellosis by targeting serotype A and D of Pasteurella multocida.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TbpB-based oral mucosal vaccine provides heterologous protection against Glasser disease caused by different serovars of Spanish field isolates of Glaesserella parasuis
Alba González-Fernández, Óscar Mencía‐Ares, … Sonia Martínez-Martínez·Porcine Health ManagementPeer-reviewed·Nov 28, 2024
- Construction of recombinant Bacillus subtilis spores surface-displaying PRRSV ORF1b, GP5, M, and N proteins in tandem and evaluation of their immunogenicity in mice
Yang Yang, Jianzhen Li, … Kangcheng Pan·bioRxiv·Jul 1, 2025
- A universal plug-and-display vaccine platform for mucosal and systemic immunity using Bacillus subtilis membrane vesicles
Kimihiro Abe, Takehito Wakabayashi, … Yukihiro Akeda·bioRxiv·Aug 15, 2026
- Characterization of Outer Membrane β-barrel Proteins of Pasteurella multocida for Multi-Epitope Vaccine Design against Human Pasteurellosis
Amisha Panda, Jahnvi Kapoor, … Anannya Bandyopadhyay·bioRxiv·Sep 15, 2026
- A surface lipoprotein on Pasteurella multocida binds complement factor I to promote immune evasion.
Quynh Huong Nguyen, Chun Heng Royce Lai, … Trevor F. Moraes·PLoS PathogensPeer-reviewed·May 6, 2025
- Addition of adjuvant to DTaP modulates vaccine-induced immunological responses but is insufficient to improve protection in CD-1 mice
K. L. Weaver, G. M. Pyles, … M. Barbier·bioRxiv·Mar 3, 2023